Terrence J. Rindler Juno Therapeutics

Mr. Rindler has been with Juno Therapeutics since 2014, establishing the initial validation programs for the company with responsibilities that included qualification of equipment, computer systems, packaging, and aseptic processes.  Today, he leads the Validation group at Juno’s multi-product clinical production facility for CAR-T cell therapies. Prior to joining Juno, he managed multiple Validation responsibilities, including aseptic process validation, for the Dendreon Corporation through the startup and approval of three commercial cellular immunotherapy facilities.